Preventing kidney damage from cisplatin chemotherapy
New mouse model of cisplatin-induced AKI and development of prevention therapy
Researchers are working to stop or reduce sudden kidney injury caused by cisplatin chemotherapy in cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11136466 on NIH RePORTER |
What this research studies
This project uses a new mouse model that mimics the sudden kidney injury many patients get from cisplatin chemotherapy and compares those findings with kidney biopsy samples from people. The team is focusing on molecules called APE2 and MYH9 that appear to cause oxidative and mitochondrial damage in kidney cells. They will test prevention therapies in mice that target these pathways and check patient tissue to confirm the relevance to humans. The goal is to identify treatments that could be moved into clinical testing to protect patients receiving cisplatin.
Who could benefit from this research
Good fit: Ideal candidates would be cancer patients receiving cisplatin chemotherapy, especially those who develop early signs of kidney injury or who can provide kidney biopsy samples.
Not a fit: People who are not treated with cisplatin or whose kidney problems come from unrelated causes are unlikely to benefit directly from this specific research.
Why it matters
Potential benefit: If successful, the work could lead to treatments that prevent or lessen acute kidney injury in patients treated with cisplatin.
How similar studies have performed: Few effective preventive therapies for cisplatin-induced AKI exist, so this builds on preliminary lab findings and represents a relatively novel approach.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Zhao, Jianjun — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Zhao, Jianjun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.